SCHEMBL25371015

SCHEMBL25371015

COc1cc(CO)c(OC)c2c1OCO2

nearest known ligand 0.67

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 0.67
ALOX15 P16050 2/20 0.67
POLB P06746 3/20 0.48
ALDH1A1 P00352 2/20 0.43
PDE4A P27815 1/20 0.43
PDE4B Q07343 1/20 0.43
PDE4C Q08493 1/20 0.43
PDE4D Q08499 1/20 0.43
MAPT P10636 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ACHE P22303 1/20 0.40
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
HTR2B P41595 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10429774 0.84 CYP3A4 (0.49) CYP3A4ALOX15POLBALDH1A1PDE4A
SCHEMBL25367786 0.83 CYP3A4 (0.67) CYP3A4ALOX15POLBALDH1A1SMN1; SMN2
SCHEMBL26060412 0.81 CYP3A4 (0.68) CYP3A4ALOX15POLBALDH1A1PDE4A
Apiol SCHEMBL29410305 0.80 CYP3A4 (1.00) CYP3A4ALOX15POLBALDH1A1SMN1; SMN2
Apiol SCHEMBL497412 0.80 CYP3A4 (1.00) CYP3A4ALOX15POLBALDH1A1SMN1; SMN2
SCHEMBL13473554 0.80 CYP3A4 (0.62) CYP3A4ALOX15POLBALDH1A1SMN1; SMN2
SCHEMBL26060390 0.79 CYP3A4 (0.57) CYP3A4ALOX15POLBALDH1A1MAPT
SCHEMBL2563162 0.78 CYP3A4 (0.60) CYP3A4ALOX15HTR2AHTR2CHTR2B
SCHEMBL26060414 0.77 CYP3A4 (0.56) CYP3A4ALOX15POLBALDH1A1SMN1; SMN2
SCHEMBL29936543 0.77 CYP3A4 (0.58) CYP3A4ALOX15POLBALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11987566-B2 Nerve damage preventing and nerve protecting compounds, preparation method thereof, pharmaceutical composition thereof, and their use GENHEALTH PHARMA CO., LTD. (TW) 2024-05-21 US claimed
EP-4230622-A1 NERVE DAMAGE PREVENTING AND NERVE PROTECTING COMPOUNDS, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION THEREOF, AND THEIR USE Genhealth Pharma Co., Ltd. (TW) 2023-08-23 EP claimed
US-20230242501-A1 NERVE DAMAGE PREVENTING AND NERVE PROTECTING COMPOUNDS, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION THEREOF, AND THEIR USE GENHEALTH PHARMA CO., LTD. (TW) 2023-08-03 US claimed
US-11987566-B2 Nerve damage preventing and nerve protecting compounds, preparation method thereof, pharmaceutical composition thereof, and their use GENHEALTH PHARMA CO., LTD. (TW) 2024-05-21 US disclosed
EP-4230622-A1 NERVE DAMAGE PREVENTING AND NERVE PROTECTING COMPOUNDS, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION THEREOF, AND THEIR USE Genhealth Pharma Co., Ltd. (TW) 2023-08-23 EP disclosed
US-20230242501-A1 NERVE DAMAGE PREVENTING AND NERVE PROTECTING COMPOUNDS, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION THEREOF, AND THEIR USE GENHEALTH PHARMA CO., LTD. (TW) 2023-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11987566-B2 Nerve damage preventing and nerve protecting compounds, preparation method thereof, pharmaceutical composition thereof, and their use NGF, GAP43, ACHE CYP3A4 4276/4885ALOX15 118/4885POLB 1130/4885
US-20230242501-A1 NERVE DAMAGE PREVENTING AND NERVE PROTECTING COMPOUNDS, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION THEREOF, AND THEIR USE NGF, GAP43, ACHE CYP3A4 4276/4885ALOX15 118/4885POLB 1130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.